CASC3 and plasma cell myeloma: BTZ is commonly used in the treatment of multiple myeloma and mantle cell non-Hodgkin’s lymphoma [61] and exerts its therapeutic action by inducing an arrest of the cell cycle, upregulating pro-apoptotic genes, and downregulating key factors of angiogenesis, stroma adhesion, cell proliferation and survival [62,63].